Explaining the limited utility of convalescent plasma from the first phase of the COVID-19 pandemic in treating those newly infected

The continued persistence of SARS-CoV-2 infections in predominantly unvaccinated individuals has meant a continued need for therapeutics to treat those hospitalized with COVID-19.